Breast Cancer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.
Early locoregional therapy with surgery and radiation does not improve overall survival (OS) in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to the results of the randomized ECOG-ACRIN E2108 phase 3 clinical trial.
Pembrolizumab (Keytruda) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
San Antonio, TX—Although capecitabine (Xeloda) is approved for metasta­tic breast cancer, it is not clear whether it should be used in early breast cancer, and its optimal role remains to be established.
Barcelona, Spain—Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting.
The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.
Two human genes, BRCA1 and BRCA2 (BRCA1/2), produce proteins that block the growth of cancer, such as breast or ovarian cancer. These proteins ensure the stability of each cell’s genetic material and help to repair damaged DNA. A mutation in either BRCA results in these proteins not functioning correctly. Specifically, DNA damage may not be repaired effectively, which can lead to cancer.
Page 1 of 10
Results 1 - 10 of 93